The food and drug addiction epidemic: Targeting dopamine homeostasis

Kenneth Blum, Panayotis K. Thanos, Gene Jack Wang, Marcelo Febo, Z. Demetrovics, Edward Justin Modestino, Eric R. Braverman, David Baron, Rajendra D. Badgaiyan, Mark S. Gold

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Obesity is damaging the lives of more than 300 million people worldwide and maintaining a healthy weight using popular weight loss tactics remains a very difficult undertaking. Managing the obesity problem seems within reach, as better understanding develops, of the function of our genome in drug/nutrient responses. Strategies indicated by this understanding of nutriepigenomics and neurogenetics in the treatment and prevention of metabolic syndrome and obesity include moderation of mRNA expression by DNA methylation, and inhibition of histone deacetylation. Based on an individual's genetic makeup, deficient metabolic pathways can be targeted epigenetically by, for example, the provision of dietary supplementation that includes phytochemicals, vitamins, and importantly functional amino acids. Also, the chromatin structure of imprinted genes that control nutrients during fetal development can be modified. Pathways affecting dopamine signaling, molecular transport and nervous system development are implicated in these strategies. Obesity is a subtype of Reward Deficiency Syndrome (RDS) and these new strategies in the treatment and prevention of obesity target improved dopamine function. It is not merely a matter of gastrointestinal signaling linked to hypothalamic peptides, but alternatively, finding novel ways to improve ventral tegmental area (VTA) dopaminergic function and homeostasis.

Original languageEnglish
Pages (from-to)6050-6061
Number of pages12
JournalCurrent Pharmaceutical Design
Volume23
Issue number39
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Substance-Related Disorders
Dopamine
Homeostasis
Obesity
Food
Ventral Tegmental Area
Phytochemicals
DNA Methylation
Dietary Supplements
Fetal Development
Metabolic Networks and Pathways
Reward
Vitamins
Histones
Nervous System
Chromatin
Weight Loss
Genome
Amino Acids
Weights and Measures

Keywords

  • Epigenetics
  • Food and drug addiction
  • Hypothalamic-gut-axis
  • Neurogenetics
  • Pro-dopamine regulation
  • Reward deficiency syndrome (RDS)

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Blum, K., Thanos, P. K., Wang, G. J., Febo, M., Demetrovics, Z., Modestino, E. J., ... Gold, M. S. (2017). The food and drug addiction epidemic: Targeting dopamine homeostasis. Current Pharmaceutical Design, 23(39), 6050-6061. https://doi.org/10.2174/1381612823666170823101713

The food and drug addiction epidemic : Targeting dopamine homeostasis. / Blum, Kenneth; Thanos, Panayotis K.; Wang, Gene Jack; Febo, Marcelo; Demetrovics, Z.; Modestino, Edward Justin; Braverman, Eric R.; Baron, David; Badgaiyan, Rajendra D.; Gold, Mark S.

In: Current Pharmaceutical Design, Vol. 23, No. 39, 01.11.2017, p. 6050-6061.

Research output: Contribution to journalReview article

Blum, K, Thanos, PK, Wang, GJ, Febo, M, Demetrovics, Z, Modestino, EJ, Braverman, ER, Baron, D, Badgaiyan, RD & Gold, MS 2017, 'The food and drug addiction epidemic: Targeting dopamine homeostasis', Current Pharmaceutical Design, vol. 23, no. 39, pp. 6050-6061. https://doi.org/10.2174/1381612823666170823101713
Blum, Kenneth ; Thanos, Panayotis K. ; Wang, Gene Jack ; Febo, Marcelo ; Demetrovics, Z. ; Modestino, Edward Justin ; Braverman, Eric R. ; Baron, David ; Badgaiyan, Rajendra D. ; Gold, Mark S. / The food and drug addiction epidemic : Targeting dopamine homeostasis. In: Current Pharmaceutical Design. 2017 ; Vol. 23, No. 39. pp. 6050-6061.
@article{3cf05b6271a14f3a8bee53a97ab7a588,
title = "The food and drug addiction epidemic: Targeting dopamine homeostasis",
abstract = "Obesity is damaging the lives of more than 300 million people worldwide and maintaining a healthy weight using popular weight loss tactics remains a very difficult undertaking. Managing the obesity problem seems within reach, as better understanding develops, of the function of our genome in drug/nutrient responses. Strategies indicated by this understanding of nutriepigenomics and neurogenetics in the treatment and prevention of metabolic syndrome and obesity include moderation of mRNA expression by DNA methylation, and inhibition of histone deacetylation. Based on an individual's genetic makeup, deficient metabolic pathways can be targeted epigenetically by, for example, the provision of dietary supplementation that includes phytochemicals, vitamins, and importantly functional amino acids. Also, the chromatin structure of imprinted genes that control nutrients during fetal development can be modified. Pathways affecting dopamine signaling, molecular transport and nervous system development are implicated in these strategies. Obesity is a subtype of Reward Deficiency Syndrome (RDS) and these new strategies in the treatment and prevention of obesity target improved dopamine function. It is not merely a matter of gastrointestinal signaling linked to hypothalamic peptides, but alternatively, finding novel ways to improve ventral tegmental area (VTA) dopaminergic function and homeostasis.",
keywords = "Epigenetics, Food and drug addiction, Hypothalamic-gut-axis, Neurogenetics, Pro-dopamine regulation, Reward deficiency syndrome (RDS)",
author = "Kenneth Blum and Thanos, {Panayotis K.} and Wang, {Gene Jack} and Marcelo Febo and Z. Demetrovics and Modestino, {Edward Justin} and Braverman, {Eric R.} and David Baron and Badgaiyan, {Rajendra D.} and Gold, {Mark S.}",
year = "2017",
month = "11",
day = "1",
doi = "10.2174/1381612823666170823101713",
language = "English",
volume = "23",
pages = "6050--6061",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "39",

}

TY - JOUR

T1 - The food and drug addiction epidemic

T2 - Targeting dopamine homeostasis

AU - Blum, Kenneth

AU - Thanos, Panayotis K.

AU - Wang, Gene Jack

AU - Febo, Marcelo

AU - Demetrovics, Z.

AU - Modestino, Edward Justin

AU - Braverman, Eric R.

AU - Baron, David

AU - Badgaiyan, Rajendra D.

AU - Gold, Mark S.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Obesity is damaging the lives of more than 300 million people worldwide and maintaining a healthy weight using popular weight loss tactics remains a very difficult undertaking. Managing the obesity problem seems within reach, as better understanding develops, of the function of our genome in drug/nutrient responses. Strategies indicated by this understanding of nutriepigenomics and neurogenetics in the treatment and prevention of metabolic syndrome and obesity include moderation of mRNA expression by DNA methylation, and inhibition of histone deacetylation. Based on an individual's genetic makeup, deficient metabolic pathways can be targeted epigenetically by, for example, the provision of dietary supplementation that includes phytochemicals, vitamins, and importantly functional amino acids. Also, the chromatin structure of imprinted genes that control nutrients during fetal development can be modified. Pathways affecting dopamine signaling, molecular transport and nervous system development are implicated in these strategies. Obesity is a subtype of Reward Deficiency Syndrome (RDS) and these new strategies in the treatment and prevention of obesity target improved dopamine function. It is not merely a matter of gastrointestinal signaling linked to hypothalamic peptides, but alternatively, finding novel ways to improve ventral tegmental area (VTA) dopaminergic function and homeostasis.

AB - Obesity is damaging the lives of more than 300 million people worldwide and maintaining a healthy weight using popular weight loss tactics remains a very difficult undertaking. Managing the obesity problem seems within reach, as better understanding develops, of the function of our genome in drug/nutrient responses. Strategies indicated by this understanding of nutriepigenomics and neurogenetics in the treatment and prevention of metabolic syndrome and obesity include moderation of mRNA expression by DNA methylation, and inhibition of histone deacetylation. Based on an individual's genetic makeup, deficient metabolic pathways can be targeted epigenetically by, for example, the provision of dietary supplementation that includes phytochemicals, vitamins, and importantly functional amino acids. Also, the chromatin structure of imprinted genes that control nutrients during fetal development can be modified. Pathways affecting dopamine signaling, molecular transport and nervous system development are implicated in these strategies. Obesity is a subtype of Reward Deficiency Syndrome (RDS) and these new strategies in the treatment and prevention of obesity target improved dopamine function. It is not merely a matter of gastrointestinal signaling linked to hypothalamic peptides, but alternatively, finding novel ways to improve ventral tegmental area (VTA) dopaminergic function and homeostasis.

KW - Epigenetics

KW - Food and drug addiction

KW - Hypothalamic-gut-axis

KW - Neurogenetics

KW - Pro-dopamine regulation

KW - Reward deficiency syndrome (RDS)

UR - http://www.scopus.com/inward/record.url?scp=85043342035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043342035&partnerID=8YFLogxK

U2 - 10.2174/1381612823666170823101713

DO - 10.2174/1381612823666170823101713

M3 - Review article

AN - SCOPUS:85043342035

VL - 23

SP - 6050

EP - 6061

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 39

ER -